![1]() - News- Inflammatory markers may explain COVID-19, diabetes dynamic- April 15, 2020- Higher levels of markers may signal greater susceptibility to cytokine storm. 
- News- Dapagliflozin trial in CKD halted because of high efficacy- March 30, 2020- An independent data monitoring committee recommended stopping the trial. 
- News- Larger absolute rivaroxaban benefit in diabetes: COMPASS- March 29, 2020- The new vascular low dose of rivaroxaban has had a slow start, but these results may stimulate use in patients with diabetes and stable disease. 
- News- Keep calm: Under 25s with diabetes aren’t being hospitalized for COVID-19- March 26, 2020- But some are concerned that type 1 diabetes diagnoses are being delayed. 
- News- FDA advises stopping SGLT2 inhibitor treatment prior to surgery- March 18, 2020- The changes affect canagliflozin, dapagliflozin, empagliflozin, and ertugliflozin, and were made because surgery may put patients taking SGLT2 inhibitors at a higher risk of ketoacidosis. 
![1]() - News- Treating COVID-19 in patients with diabetes- March 17, 2020- Most health advisories about COVID-2019 mention diabetes as one of the high-risk categories for the disease. 
- News- COVID-19: Extra caution needed for patients with diabetes- March 17, 2020- Coexisting heart disease, kidney disease, advanced age, and frailty are likely to further increase the severity of disease. 
- News- MACE benefits with dapagliflozin improve with disease duration- March 4, 2020- Findings suggest treatment with the SGLT-2 inhibitor should be initiated early in some high-risk patients. 
![1]() - Opinion- Can this patient get IV contrast?- March 2, 2020- Patients with seafood allergy have a higher rate of reactions to iodinated contrast, but not at a higher rate than patients with other food allergies. 
![1]() - News- Noninjectable modes of insulin delivery coming of age- February 2, 2020- Intranasally delivered insulin may also improve neurocognitive function. 



